SCHEDULE 13G/A: BlackRock Discloses 8.2% Passive Stake in Nurix Therapeutics

BlackRock, Inc. has filed an amended Schedule 13G, reporting an 8.2% passive beneficial ownership stake in Nurix Therapeutics, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 6,284,116 shares of Nurix Therapeutics, Inc. common stock.
• This ownership represents 8.2% of the total outstanding common shares of Nurix Therapeutics, Inc.
• BlackRock holds sole voting power over 6,196,086 shares and sole dispositive power over 6,284,116 shares.
• The shares were acquired and are held in the ordinary course of business, explicitly not for the purpose of changing or influencing control of the issuer.
• No single person's interest within BlackRock's reported holdings is more than 5% of the total outstanding common shares.

Sentiment

Score: 6

Explanation: The filing is neutral in tone, as expected for a Schedule 13G. The disclosure of a significant passive stake by a major institutional investor like BlackRock can be viewed as a slightly positive signal of confidence in the company, hence a slightly positive score.

Positives

• BlackRock, a prominent global institutional investor, holds a significant 8.2% stake, which can be interpreted as a vote of confidence in Nurix Therapeutics, Inc.
• The filing indicates a passive investment strategy, suggesting that BlackRock does not intend to actively influence or seek control over Nurix Therapeutics, Inc.'s management or operations.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding Nurix Therapeutics, Inc.'s future performance or BlackRock's future investment intentions beyond the passive nature of the current holding.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing reflects a standard disclosure by a large institutional asset manager regarding its passive investment in a publicly traded company. It does not provide specific insights into broader industry trends or competitive dynamics, but rather details a significant ownership stake by a major financial institution.

Comparison to Industry Standards

• This document is a standard regulatory filing (Schedule 13G) for disclosing passive beneficial ownership exceeding 5%.
• BlackRock, Inc. is one of the world's largest asset managers, and its significant, passive equity holdings in various public companies, such as this 8.2% stake in Nurix Therapeutics, Inc., are consistent with typical large-cap fund management strategies.
• Such filings are routine disclosures for institutional investors maintaining non-controlling positions, aligning with global benchmarks for transparency in capital markets.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional ownership stake, potentially influencing investor sentiment due to BlackRock's presence.
• Company Management: Awareness of a large, passive institutional holder, which typically implies less direct engagement on operational matters unless the stake becomes active.

Next Steps

• BlackRock, Inc. will continue to file amendments to this Schedule 13G if there are material changes to its beneficial ownership of Nurix Therapeutics, Inc. common stock, or if its ownership falls below the 5% threshold.

Key Dates

Keywords

Nurix Therapeutics, BlackRock, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Passive Investment, SEC Filing